Images |
Sources |
Experiment + Assay |
Phenotypes |
Human Diseases |
No Image
|
Fig. 2B
Flach H et al. (2022)
|
Xla Wt + glyphosate [121.5]
NF28 (in situ hybridization)
|
|
|
No Image
|
Fig. 2B
Flach H et al. (2022)
|
Xla Wt + glyphosate [243]
NF28 (in situ hybridization)
|
|
|
|
Fig.3.C
Pokrovsky D et al. (2021)
|
Xla Wt + hydroxyurea + aphidicolin
NF32 (in situ hybridization)
|
|
|
|
Fig.1.C,D
Smith SJ et al. (2020)
|
Xla Wt + adprhl1 MO
NF40 (in situ)
|
|
|
|
Fig.6.B,C
Smith SJ et al. (2020)
|
Xla Wt + adprhl1 MO
NF40 (in situ)
|
|
|
|
Fig. 6. CD
Smith SJ et al. (2020)
|
Xla Wt + adprhl1 CRISPR
NF33-39 (in situ)
|
|
|
|
Fig.1.E,F
Smith SJ et al. (2020)
|
Xla Wt + adprhl1 MO
NF40 (in situ)
|
|
|
|
Fig. S3 B
Yasuoka Y et al. (2014)
|
Xla Wt + tle1 + gsc + otx2 + ssbp3 + ldb1 + lhx1 mRNA
NF9 (RT-PCR)
|
|
|
|
Fig. 5 CFI
Langdon Y et al. (2012)
|
Xla Wt + ptpn11N308D
NF37/38 (immunohistochemistry)
|
|
Noonan syndrome
|